McMullen Michael R. 4

What Happened Michael R. McMullen, a director of Bristol Myers Squibb (BMY), received a grant of 3,996.367 Deferred Share Units (DSUs) on 2026-02-01. The grant is reported as an award/derivative (Code A) with a per-unit reference price of $55.05, for a total value of $220,000. This was a compensation award — not an open‑market purchase or a sale.

Key Details

• Transaction date: 2026-02-01; Form 4 filed 2026-02-03.
• Transaction type/code: Award/Grant (A) of Deferred Share Units (derivative).
• Units granted: 3,996.367 DSUs at $55.05 per unit; reported total value $220,000.
• Shares owned after transaction: Not disclosed in this filing.
• Footnotes:
  • F1: Each DSU will convert into a share of common stock upon settlement; DSUs become settleable when the director leaves or on a pre‑specified future date.
  • F2: Grant includes deferred compensation and reinvested dividends under the 1987 Deferred Compensation Plan for Non‑Employee Directors.

Context Deferred Share Units are a common form of director compensation that convert into actual shares at settlement (typically when the director leaves or at a selected future date). Such awards reflect compensation policy rather than a direct market sentiment signal; they do not represent an immediate cash purchase or sale of shares.